WHWK
Whitehawk Therapeutics Inc (WHWK) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
Revenue and operating profit margins remain at 0, indicating no demonstrated growth engine in the TTM data.
Negative TTM operating cash flow and free cash flow per share suggest the business is not yet scaling profitably.
Profitability
TTM return on equity, assets, and invested capital are all negative, showing the company is currently destroying capital.
EBITDA, EBIT, pretax, and net profit margins are all 0 in the latest ratios, reinforcing the lack of profitability.
Financial Health
Liquidity is very strong with a current ratio of 17.38 and cash ratio of 7.70, giving the company substantial near-term flexibility.
Balance-sheet leverage appears limited in the reported ratios, but solvency metrics are distorted and should be interpreted cautiously given the negative operating profile.
Reinvestment Capital Efficiency
Return on invested capital is negative, indicating reinvested capital is not generating acceptable returns.
Cash conversion is poor, with negative operating cash flow and free cash flow per share despite a large working-capital base.
Valuation
Valuation looks optically cheap on price-to-book at 2.09 and enterprise value to sales is unavailable/zero, but the lack of earnings and cash flow makes those multiples hard to trust.
Negative earnings and cash flow yields indicate the market is pricing in a turnaround rather than rewarding current fundamentals.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Whitehawk Therapeutics Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

